NCT05825014 Predicting Adverse Outcomes Using Machine Learning of COPD Patients in Hong Kong
| NCT ID | NCT05825014 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | COPD Exacerbation |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2023-08-29 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2023-08-29 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop predictive models for patients with a diagnosis of COPD at discharge of an index admission on these outcomes using machine learning: Primary outcome: Early admission Secondary outcomes: 1. Frequent readmission 2. Composite outcome (Early + Frequent readmissions) 3. Mortality 4. Longstayers
Eligibility Criteria
Inclusion Criteria: * ≥40 years * Patients are discharged from 2016 -2022 * Discharge Diagnosis: Using the Discharge Diagnosis ICD Codes found in the Primary Diagnosis to determine if a patient has COPD * Validated against Spirometry results (for patient with a spirometry reading): Spirometry reading taken from anytime point before. Patient should have Post FEV1/FVC ratio of \< 0.7 in any one of the spirometry readings. If Post FEV1/FVC is not available, we will check if patients have a Pre FEV1/FVC value, and will also include patients with Pre FEV1/FVC ratio of \< 0.7 in any one of the spirometry readings. Exclusion Criteria: * Admission diagnosis due to causes other than COPD
Contact & Investigator
David Hui, MD
STUDY DIRECTOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05825014 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying COPD Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05825014 currently recruiting?
Yes, NCT05825014 is actively recruiting participants. Contact the research team at fannyko@cuhk.edu.hk for enrollment information.
Where is the NCT05825014 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05825014 clinical trial?
NCT05825014 is sponsored by Chinese University of Hong Kong. The principal investigator is David Hui, MD at Chinese University of Hong Kong. The trial plans to enroll 100,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.